Epygenix declares 1st patient dosed successfully in EPX-100’s Phase 2
Category : #Health  By- Madhura Dethe  Date: 2020-11-13
  • share
  • Twitter
  • Facebook
  • LinkedIn
Epygenix declares 1st patient dosed successfully in EPX-100’s Phase 2

Biopharmaceutical major, Epygenix Therapeutics, Inc., has reportedly announced its success with the dosing of the first patient in a randomized, placebo-controlled, double-blind, Phase 2 trial of EPX-100 as an Adjunctive Therapy for children diagnosed with Dravet Syndrome. The trial is meant for assessing the safety and efficiency of EPX-100 in children having Dravet Syndrome and the company is in the process of recruiting 24 patients for the completion of this study.

According to Epygenix Chair, Alex Yang, J.D., LLM, owing to its superb safety profile and robust science background, the company is cautiously optimistic that EPX-100 will bring out excellent results in this study and take another pace towards the development of the best-in-class refractory epilepsies drug.

Epygenix President and CEO, Dr. Hahn-Jun Lee, M.Sc., Ph.D., has also expressed the company’s pleasure in the announcement of these results. Lee has further opined that first patient dosing is a highly significant clinical milestone of EPX-100 in Dravet patients. The company has made substantial efforts so far and will consistently work to gain meaningful clinical results for these patients, added Lee.

Dravet Syndrome is a lifelong, rare, and catastrophic form of epilepsy that commences in the first year of life with prolonged or frequent seizures. Increased mortality, intellectual disability, behavioral abnormalities, and gait and motor dysfunction are commonly observed in patients with the advancement of this disease.

For the uninitiated, Epygenix Therapeutics, Inc., specializes in the discovery and development of drugs for the treatment of intractable and rare genetic epilepsy in childhood, comprising Dravet Syndrome. The company is presently working towards the development of EPX-100, EPX-200, and EPX-300 drug candidates. These candidates are supposed to abolish electrographic seizure activity and convulsive behavior, discovered in a zebrafish Dravet Syndrome model, which shows considerable resemblance to human pathology and further authenticates its validity by the human efficacy with EPX-300 and EPX-200.

 

Source Credits:

https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-successfully-dosed-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301171444.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Madhura Dethe    

Madhura Dethe

Having pursued a post graduate degree in English Literature, Madhura’s interest naturally drifted toward writing. Presently, she works as an associate content writer for lunchwithapunch.com and pens down insightful articles on healthcare, technology, and business tr...

Read More

Most Read

Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
By- Puja More  Date: 2020-12-03

Biohaven Pharmaceutical Holding Company and Sosei Group Corporation have signed a collaboration and licensing agreement under which the form...

Cerus receives FDA nod for INTERCEPT Blood System for Cryoprecipitation
Cerus receives FDA nod for INTERCEPT Blood System for Cryoprecipitation
By- Madhura Dethe  Date: 2020-12-02

Adding to yet other initiatives and accomplishments in the medical fraternity, a California-based pathogen-protected blood component develop...

Nigeria set to commence installation of 5Mn solar home power systems
Nigeria set to commence installation of 5Mn solar home power systems
By- Puja More  Date: 2020-12-01

The first phase of installation is expected to be commenced in December 2020 nationwide. The Federal Government of Nigeria has recently sta...

Ascentage partners with U-M to attain license for a MDM2 degrader
Ascentage partners with U-M to attain license for a MDM2 degrader
By- Puja More  Date: 2020-11-30

Acquisitions, collaborations, and mergers have become a common practice in the medical and biotechnology sector in recent years. Speaking of...

Our Conrtributor

Prince Charles urges companies to join Terra Carta, the Earth charter

Prince Charles urges companies to join Terra Carta, the Earth charter

By- Madhura Dethe

The Prince of Wales is urging companies to invest in a more sustainable future and contribute more t...

Samsung working on 600 MP camera sensor, can zoom in 4k and 8K videos

Samsung working on 600 MP camera sensor, can zoom in 4k and 8K videos

By- Madhura Dethe

In February 2020, the South Korean multinational conglomerate company- Samsung had launched the 108M...

India expected to emerge as the largest COVID-19 vaccine buyer

India expected to emerge as the largest COVID-19 vaccine buyer

By- Madhura Dethe

With more than 40,000 COVID-19 cases being diagnosed daily in the country, India is all set to emerg...